Author: admin

New research has found it takes an average of 3.5 years for a person with dementia to receive a diagnosis after experiencing the first symptoms. For people with early-onset dementia, the delay is even longer, 4.1 years.

Many people and their families “may be living with uncertainty, and without access to the support, care, and planning resources they need,” says senior study author Vasiliki Orgeta, PhD, an associate professor of psychiatry at University College London in England.

The findings also highlight the urgent need to improve public awareness and training for healthcare providers and to streamline the referral process, says Dr. Orgeta.

Even though the vast majority of people with multiple sclerosis are female, women are far less likely than men with this condition to receive medications that can relieve symptoms or slow disease progression, a new study suggests.

Researchers examined more than a decade of data on nearly 23,000 people with MS who were between 18 and 40 years old. Participants were 29 years old on average at diagnosis, and roughly 3 in 4 were women.

“This is extremely alarming,” says Ann Marie Murray, MD, a professor and the chief of comprehensive movement disorders at the Rockefeller Neuroscience Institute at West Virginia University in Morgantown.

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous

Newswise — A recent multicenter clinical trial has uncovered inflammatory pathways that contribute to asthma flare-ups in children that occur despite treatment, according to findings published in JAMA Pediatrics.

Eosinophilic asthma is characterized by high levels of eosinophils, a type of white blood cell involved in the body’s immune response. While eosinophils typically help fight infections, in eosinophilic asthma, they accumulate in the lungs and airways, causing chronic inflammation, swelling and damage to the respiratory system.

Eosinophilic asthma is driven by type 2 (T2) inflammation, an immune response involving cytokines that promote the production and activation of eosinophils. Because of this, therapies targeting T2 inflammation are used to reduce eosinophil levels and prevent asthma flare-ups.

But even with targeted therapies against T2 inflammation, some children still experience asthma attacks. This suggests that other inflammatory pathways also play a role in exacerbations, said Rajesh Kumar, MD, Interim Division Head of Allergy and Immunology at Ann & Robert H. Lurie Children’s Hospital of Chicago, who was a co-author of the paper.

In the study, scientists analyzed data from a previous clinical trial studying respiratory illnesses in children with eosinophilic asthma living in low-income urban areas across nine U.S. cities. Investigators compared the effects of mepolizumab—a biologic therapy that targets T2 inflammation—with a placebo over a 52-week period.

While mepolizumab significantly reduced the expression of eosinophil-associated T2 inflammation during asthma flare-ups, exacerbations still occurred.

“The previous trial raised questions about what happens when you take away some of the allergic inflammation using a biologic drug, and why is it that some children experience exacerbations and some don’t?” Dr. Kumar said. “Different types of inflammation–allergic and different types of nonallergic inflammation–interact with exacerbations, both viral and non-viral. We wanted a more precise way of understanding what’s driving some of the exacerbations in kids.”

By employing RNA sequencing of nasal samples collected during 176 episodes of acute respiratory illness, investigators identified three distinct inflammatory drivers of asthma exacerbations. The first were epithelial inflammatory pathways, which were increased in children receiving mepolizumab, regardless of viral infection. The second was macrophage-driven inflammation, which was specifically linked to viral respiratory illnesses, and the third involved mucus hypersecretion and cellular stress responses, which were elevated in both treatment and placebo groups during flare-ups.

“We found that children who still exacerbated on the drug had less of this allergic type of inflammation, but they had other residual epithelial pathways which were driving some of that inflammatory response that was involved in exacerbation,” Dr. Kumar said.

The study highlights the complexity of asthma in children and underscores the need for more personalized treatment strategies, Dr. Kumar said.

“There are multiple different types of inflammatory responses that are involved in exacerbations, and they’re driving exacerbations differentially based on whether patients have a virus or are taking drugs to block different parts of the inflammatory response,” Dr. Kumar said.

As asthma continues to affect children in urban communities disproportionately, the insights from the study could pave the way for precision interventions for children based on the type of inflammation driving their asthma, and lead to improved quality of life for young patients, Dr. Kumar said.

“This study gives us a better understanding of what results in persistent exacerbations and opens up the potential for new therapies or combinations of therapies based upon that.”

The study was supported by a National Institutes of Health grant (UM1AI11427).

Ann & Robert H. Lurie Children’s Hospital of Chicago is a nonprofit organization committed to providing access to exceptional care for every child. It is the only independent, research-driven children’s hospital in Illinois and one of less than 35 nationally. This is where the top doctors go to train, practice pediatric medicine, teach, advocate, research and stay up to date on the latest treatments. Exclusively focused on children, all Lurie Children’s resources are devoted to serving their needs. Research at Lurie Children’s is conducted through Stanley Manne Children’s Research Institute, which is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children’s is the pediatric training ground for Northwestern University Feinberg School of Medicine. It is ranked as one of the nation’s top children’s hospitals by U.S. News & World Report.